Related Experiment Videos
Novel therapies for Helicobacter pylori infection
A R Opekun1, H M El-Zaimaity, M S Osato
1Department of Medicine, Baylor College of Medicine, Texas Children's Hospital, Veterans Affairs Medical Center, Houston 77030, USA.
Background:
Increasing antibiotic resistance has begun to impair our ability to cure Helicobacter pylori infection.
Aim:
To evaluate orally administered novel therapies for the treatment of H. pylori infection.
Methods:
Healthy H. pylori infected volunteers received: (a) hyperimmune bovine colostral immune globulins, (b) an oligosaccharide containing an H. pylori adhesion target, Neu5Aca2-3Galb1-4Glc-(3'-sialyllactose), or (c) recombinant human lactoferrin. Outcome was assessed by urea breath test or histological assessment of the number of H. pylori present.
Results:
None of the novel therapies appeared effective and no adverse events occurred.
Conclusion:
Although in vitro data appeared promising, in vivo results were disappointing. Higher doses, longer duration of therapy, adjunctive acid suppression, or a combination could possibly yield better results.